ORPH
Orphazyme A/S [ORPH] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ORPH Stock Summary
In the News
ORPH Financial details
Company Rating
Neutral
Market Cap
0
Income
-485.37M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
180
Optionable
No
Shortable
Yes
Earnings
05 Apr 2022
P/E
-0.27
Forward P/E
-
PEG
-0.06
P/S
-
P/B
0.27
P/C
-
P/FCF
-
Quick Ratio
4.47
Current Ratio
4.7
Debt / Equity
0.35
LT Debt / Equity
0.14
-
-
EPS (TTM)
-24.26
EPS next Y
-
EPS next Q
-
EPS this Y
32.31%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
51.91%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0%
Inst Trans
0%
ROA
-77%
ROE
-188%
ROC
-0.95%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.8457-0.955
52W High
-
52W Low
-
RSI
-
Rel Volume
0.68
Avg Volume
1.38M
Volume
941.41K
Perf Week
0%
Perf Month
-
Perf Quarter
-
Perf Half Y
157.47%
-
-
-
-
Beta
0.80232
-
-
Volatility
0%, 0.13%
Prev Close
0%
Price
0.87
Change
2.87%
ORPH Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-12-31
| Metric | History | 2016-12-31 | 2017-12-31 | 2018-12-31 | 2019-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -5.65 | -10.46 | -11.5 | -16.87 | -22.32 | |
| Operating cash flow per share | -5.34 | -7.91 | -11.76 | -16.34 | -19 | |
| Free cash flow per share | -5.36 | -8.03 | -11.88 | -16.5 | -19.18 | |
| Cash per share | 1.4 | 52.36 | 19.77 | 6.18 | 25.63 | |
| Book value per share | 1.71 | 51.04 | 19.45 | 2.65 | 21.88 | |
| Tangible book value per share | 1.71 | 50.22 | 18.91 | 2.12 | 21.44 | |
| Share holders equity per share | 1.71 | 51.04 | 19.45 | 2.65 | 21.88 | |
| Interest debt per share | 0.01 | 0.05 | 0.17 | 4.1 | 2.99 | |
| Market cap | 699.64M | 723.11M | 1.27B | 1.3B | 1.84B | |
| Enterprise value | 685.29M | 91.37M | 870.64M | 1.25B | 1.19B | |
| P/E ratio | -12.08 | -5.73 | -5.51 | -3.84 | -2.91 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -12.78 | -7.58 | -5.39 | -3.96 | -3.42 | |
| PFCF ratio | -12.73 | -7.46 | -5.34 | -3.92 | -3.38 | |
| P/B Ratio | 39.96 | 1.17 | 3.26 | 24.46 | 2.97 | |
| PTB ratio | 39.96 | 1.17 | 3.26 | 24.46 | 2.97 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -10.94 | -0.7 | -3.78 | -3.73 | -1.92 | |
| EV to operating cash flow | -12.52 | -0.96 | -3.71 | -3.82 | -2.2 | |
| EV to free cash flow | -12.47 | -0.94 | -3.67 | -3.78 | -2.18 | |
| Earnings yield | -0.08 | -0.17 | -0.18 | -0.26 | -0.34 | |
| Free cash flow yield | -0.08 | -0.13 | -0.19 | -0.25 | -0.3 | |
| Debt to equity | 0 | 0 | 0 | 1.46 | 0.11 | |
| Debt to assets | 0 | 0 | 0 | 0.43 | 0.09 | |
| Net debt to EBITDA | 0.23 | 4.84 | 1.71 | 0.14 | 1.07 | |
| Current ratio | 1.93 | 13.75 | 7.99 | 2.25 | 4.7 | |
| Interest coverage | -892.45 | -202.56 | -67.09 | -70.41 | -44 | |
| Income quality | 0.94 | 0.76 | 1.02 | 0.97 | 0.85 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0.01 | 0.02 | 0.06 | 0.02 | |
| Capex to operating cash flow | 0 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.34 | -2.38 | -1.72 | -0.86 | -0.98 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 14.74 | 109.6 | 70.93 | 31.71 | 104.82 | |
| ROIC | -3.31 | -0.2 | -0.58 | -2.33 | -0.88 | |
| Return on tangible assets | -1.81 | -0.19 | -0.53 | -1.98 | -0.78 | |
| Graham Net | 0.64 | 49.47 | 17.65 | 0.21 | 18.99 | |
| Working capital | 13.46M | 600.84M | 370.39M | 82.24M | 617.04M | |
| Tangible asset value | 17.51M | 605.85M | 377.51M | 42.43M | 608.07M | |
| Net current asset value | 13.46M | 600.84M | 370.28M | 20.44M | 581.7M | |
| Invested capital | 0 | 0 | 0 | 1.46 | 0.11 | |
| Average receivables | 7.72M | 12.57M | 15.33M | 12.86M | 14.87M | |
| Average payables | 3.58M | 9.08M | 15.76M | 9.59M | 15.52M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -3.31 | -0.2 | -0.59 | -6.37 | -1.02 | |
| Capex per share | -0.02 | -0.12 | -0.12 | -0.16 | -0.18 |
Quarterly Fundamentals Overview
Last date of statement is 2021-06-30 for Q2
| Metric | History | 2019-06-30 | 2019-12-31 | 2020-06-30 | 2020-12-31 | 2021-06-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -4.22 | 0 | -6.28 | -9.54 | 0 | |
| Operating cash flow per share | -4.08 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | -4.13 | 0 | -0.03 | -0.03 | 0 | |
| Cash per share | 11.28 | 0 | 30.52 | 36.34 | 0 | |
| Book value per share | 11.24 | 0 | 25.3 | 31.02 | 0 | |
| Tangible book value per share | 10.72 | 0 | 25.3 | 30.4 | 0 | |
| Share holders equity per share | 11.24 | 0 | 25.3 | 31.02 | 0 | |
| Interest debt per share | 0.54 | 0 | 3.85 | 3 | 0 | |
| Market cap | 1.28B | 0 | 1.29B | 1.3B | 0 | |
| Enterprise value | 1.07B | -46.48M | 756.8M | 642.18M | -275.59M | |
| P/E ratio | -3.81 | 0 | -2.56 | -1.7 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -15.72 | 0 | 0 | 0 | 0 | |
| PFCF ratio | -15.57 | 0 | -2.2K | -2.17K | 0 | |
| P/B Ratio | 5.71 | 0 | 2.54 | 2.09 | 0 | |
| PTB ratio | 5.71 | 0 | 2.54 | 2.09 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -12.78 | 0 | -5.84 | -3.21 | 0 | |
| EV to operating cash flow | -13.08 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | -12.95 | 0 | -1.29K | -1.07K | 0 | |
| Earnings yield | -0.07 | 0 | -0.1 | -0.15 | 0 | |
| Free cash flow yield | -0.06 | 0 | 0 | 0 | 0 | |
| Debt to equity | 0.04 | 1.46 | 0.16 | 0.11 | 0.35 | |
| Debt to assets | 0.03 | 0.43 | 0.12 | 0.09 | 0.14 | |
| Net debt to EBITDA | 2.58 | 0 | 4.09 | 3.28 | 0 | |
| Current ratio | 5.54 | 2.25 | 5.24 | 4.7 | 1.8 | |
| Interest coverage | -70.41 | 0 | 32.81 | 18.98 | 0 | |
| Income quality | 0.97 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.04 | 0.06 | 0 | 0.02 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.86 | 0 | -0.52 | -0.41 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 32.66 | 0 | 59.82 | 81.62 | 0 | |
| ROIC | -0.34 | 0 | -0.22 | -0.29 | 0 | |
| Return on tangible assets | -0.31 | 0 | -0.19 | -0.24 | 0 | |
| Graham Net | 9.34 | 0 | 23.05 | 26.94 | 0 | |
| Working capital | 201.6M | 82.24M | 516.38M | 617.04M | 180.04M | |
| Tangible asset value | 214.32M | 42.43M | 506.14M | 608.07M | 166.76M | |
| Net current asset value | 191.94M | 20.44M | 467.97M | 581.7M | 142.43M | |
| Invested capital | 0.04 | 1.46 | 0.16 | 0.11 | 0.35 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 0 | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.38 | 0 | -0.25 | -0.31 | 0 | |
| Capex per share | -0.04 | 0 | -0.03 | -0.03 | 0 |
ORPH Frequently Asked Questions
What is Orphazyme A/S stock symbol ?
Orphazyme A/S is a DK stock and trading under the symbol ORPH
What is Orphazyme A/S stock quote today ?
Orphazyme A/S stock price is $0.87 today.
Is Orphazyme A/S stock public?
Yes, Orphazyme A/S is a publicly traded company.
Company Profile
- Volume Average 1.38M
- Employee 180
- CEO Ms. Kim Stratton
- Headquarters Copenhagen,DK
- IPO Date 2020-09-04
-
Website
https://www.orphazyme.com 
Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
